Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9392559 | 0.87 | MAPT (0.43) | MAPTRAB9AGAAARSMN1; SMN2 | |
| SCHEMBL5773388 | 0.84 | TARBP2 (0.48) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL343836 | 0.82 | HTT (0.50) | MAPTRAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5771735 | 0.82 | ALDH1A1 (0.50) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL10668171 | 0.82 | SMN1; SMN2 (0.52) | MAPTRAB9APRKCZSMN1; SMN2ALDH1A1 | |
| SCHEMBL11384351 | 0.82 | ALDH1A1 (0.48) | MAPTRAB9AGAAPRKCZSMN1; SMN2 | |
| SCHEMBL6502372 | 0.81 | TSHR (0.53) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5776864 | 0.81 | GAA (0.51) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3552361 | 0.80 | HPGD (0.43) | MAPTRAB9AARSMN1; SMN2ALDH1A1 | |
| SCHEMBL3549592 | 0.80 | TDP1 (0.46) | MAPTRAB9AGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-4243406-A | REDUCING INJURIES TO CROP PLANTS WHEN USING AN ALPHA-HALOACETANILIDE AS A HERBICIDE | MONSANTO COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MAPT 4701/4885RAB9A 3076/4885GAA 2207/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MAPT 4763/4885RAB9A 3507/4885GAA 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.